The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2020 | Genetic profiling of multiple myeloma in the novel agents era
Niccolò Bolli, MD, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, outlines the role of genetic profiling in multiple myeloma. Dr Bolli discusses the molecular heterogeneity of molecular myeloma and its importance in disease classification as well as precision medicine and highlights venetoclax, a BCL-2 inhibitor, which is effective in only a specific molecular subtype of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
